Abstract:Several hepatitis B virus (HBV) serum markers have been identified as risk factors for liver fibrosis in patients with chronic HBV infection, and several noninvasive fibrosis tests based on serum indexes are now used to identify the severity of liver fibrosis. We aimed to identify the relationship between hepatitis B core-related antigen (HBcrAg) serum levels and liver fibrosis in treatment-naive chronic HBV infection patients. A total of 246 treatment-naive chronic HBV infection patients were enrolled in this study. All of the patients underwent liver biopsies at baseline. Using the METAVIR fibrosis stages, there were 15, 140, 50, 26 and 15 patients in the F0, F1, F2, F3 and F4 stages (METAVIR scoring system), respectively. The biochemical, serological and virological parameters were measured using standard laboratory procedures. The HBcrAg serum levels of the patients were examined via ELISA. HBcrAg serum levels of F2, F3 and F4 stage patients were significantly higher than those of nonsignificant liver fibrosis patients (METAVIR F0-F1), but there were no significant differences among F2, F3 and F4 stage patients. Serum HBcrAg (OR, 2.18; 95% confidence interval [CI], 1.51-3.16), albumin (ALB) (OR, 0.60; 95% CI, 0.41-0.87), prothrombin activity (PTA) (OR, 0.58; 95% CI, 0.40-0.83) and platelet (PLT) counts (OR, 0.38; 95% CI, 0.25-0.57) were associated with significant liver fibrosis (METAVIR F2-F4). The serum HBcrAg value enabled the correct identification of patients with significant fibrosis, with an area under the receiver operating characteristic curve of 0.81 (95% CI, 0.75-0.88). The APRI, FIB-4 index and ALBI score can identify significant liver fibrosis with an area under the ROC curve of 0.74 (95% CI, 0.66-0.81), 0.73 (95% CI, 0.65-0.80) and 0.63 (95% CI, 0.55-0.72), respectively. Compared with these three indexes, the accuracy rate of diagnosis of significant fibrosis based on HBcrAg was higher than that of the FIB-4 index (p = 0.0479) and ALBI score (p = 0.0030). HBcrAg, ALB, PTA serum levels and PLT counts were associated with significant liver fibrosis in treatment-naive chronic HBV infection patients. HBcrAg serum levels enabled the correct identification of patients with significant fibrosis (METAVIR F2-F4), and HBcrAg was more effective than the FIB-4 index and ALBI score.

Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Effect of Serum Hepatitis B Surface Antigen Levels on Predicting the Clinical Outcomes of Chronic Hepatitis B Infection: A Meta‐analysis

Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients

The Clinical Value of Serum Hepatic Parenchyma Cell Volume-Normalized Hepatitis B Surface Antigen Levels in Hepatitis B E Antigen -Positive and -Negative Chronic Hepatitis B Patients

Association Between Serum Levels Of Hepatitis B E-Antigen And Severity Of Liver Fibrosis

Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.

Hepatitis B Surface Antigen Levels Can Be Used to Rule out Cirrhosis in Hepatitis B E Antigen-Positive Chronic Hepatitis B: Results from the SONIC-B Study.

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Serum HBeAg and HBV DNA Levels Are Not Always Proportional and Only High Levels of HBeAg Most Likely Correlate with High Levels of HBV DNA: A Community-Based Study.

Serum Hepatitis B Surface Antigen Quantification As A Useful Assessment for Significant Fibrosis in Hepatitis B E Antigen-Positive Hepatitis B Virus Carriers

Serum Immunoglobulin A (iga) Level is a Potential Biomarker Indicating Cirrhosis During Chronic Hepatitis B Infection

Correlations between serum hepatitis B core-related antigen and hepatitis B surface antigen in patients with hepatitis B cirrhosis and a hepatitis B virus-DNA-negative status: a retrospective study.

Detection of serum large and middle hepatitis B virus surface proteins: A novel potential diagnostic and prognostic biomarker for chronic hepatitis B

Serum Hepatitis B Surface Antigen Titer and Transient Elastography in Screening for Insignificant Fibrosis in HBeAg-positive Chronic Hepatitis B Patients

Correlations Among Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Titers and Viral Load in Chinese Patients with Chronic Hepatitis B.

Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase

Serum Hepatitis B Surface Antigen Correlates with Fibrosis and Necroinflammation: A Multicentre Perspective in China

Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naive chronic HBV infection patients